India is shifting towards the phase of epidemiological transition where ageing and chronic disorders are at its peak which eventually results in the limitation of quality of life . The studies shows that the different range of orthopedic pain which is so common that it is reported by all age group of  people during their period of life. In the year 2008, the esteemed Drug Controller General of India granted approval for the IM etoricoxib injection, formulated at a concentration of 90 mg per mL, to be administered for the alleviation of short-term acute painful conditions in adults.

Furthermore, IM injection can be particularly beneficial for patients who cannot tolerate or effectively absorb oral medications. As the global population ages, the prevalence of  pain conditions, such as osteoarthritis, neuropathy, and other musculoskeletal disorders, is increasing, necessitating the frequent use of pain-relieving medications.  pain-relieving medication, it is crucial to consider the potential misuse of these drugs. With this novel route of administration, the frequency of drug administration can be minimized, potentially reducing the cost of a single dose. COX-1-derived prostanoids are essential for ‘housekeeping ‘functions throughout the body and especially in the GI tract, kidney and platelets. PGE2 , for example, is recognised as an essential component for the maintenance of gastrointestinal mucosal integrity which it orchestrates by maintaining sub-mucosal blood flow, amongst other actions.

This study compares the efficacy and safety of intramuscular etoricoxib (90 mg/mL) versus diclofenac sodium (75 mg/mL) for managing acute orthopedic pain. It is a randomized, open-label pilot trial involving 70 patients aged 18-60 with conditions like fractures, arthritis, or sprains. Pain relief is measured using the Visual Analog Scale (VAS) at 30 and 60 minutes post-injection. The primary goal is to determine if etoricoxib provides faster or better pain relief than diclofenac, while secondary objectives assess safety and side effects. The study aims to establish IM etoricoxib as a viable alternative with fewer gastrointestinal risks compared to traditional NSAIDs like diclofenac. Ethical approvals and informed consent are secured.

This study has the primary goal to evaluate the safety and efficacy of IM etoricoxib and IM diclofenac sodium in patients with acute orthopaedic pain. To access the symptoms relief using pain scale based on the effect of treatment.